EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies

Jean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, Joanne Rizzo, Kristina Kligys, Jenny Griffith, Javier Zambrano, Qian Zhou, Yafei Zhang, Jasmina Kalabic, Florian Rieder, Marla C Dubinsky und 1 weitere

Journal of Crohn's and Colitis · 03.06.2024 · 18 (6) · 818-827

DOI: 10.1093/ecco-jcc/jjad206 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Crohn's and Colitis, online erschienen am 09.12.2023. Verfasst von Jean-Frederic Colombel und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Hauptthemen laut MEDLINE: Crohn Disease, Antibodies, Monoclonal. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Crohn’s disease [CD] symptoms are a main driver for impaired quality of life, and fast relief is important for patient care. Stool frequency [SF] and abdominal pain score [APS] are patient-reported outcomes [PROs] measuring symptom severity, which are supported as treatment targets by the STRIDE-II consensus. This post hoc analysis examined the efficacy of risankizumab [RZB], a humanised monoclonal antibody with high specificity for interleukin-23 p19, for providing early symptom relief, along with the prognostic value of early symptom relief for achieving future clinical and endoscopic endpoints.

Methods

Individual and combined measures of SF and AP at Weeks 1, 2, and 3 were assessed in patients with moderate to severe CD who received 600 mg intravenous RZB or placebo [PBO] in the ADVANCE or MOTIVATE induction studies. Multivariate logistic regression was used to examine the predictiveness of early symptom improvement for clinical and endoscopic outcomes following RZB induction and maintenance.

Results

Higher rates of SF/APS clinical remission and enhanced clinical response were observed as early as Week 1 with RZB vs PBO. A larger proportion of patients achieved clinical endpoints with RZB vs PBO, irrespective of prior bio-failure status. Early PRO improvement was associated with a greater likelihood of achieving clinical and endoscopic improvement following 12-week induction and 52-week maintenance RZB dosing.

Conclusions

After the first intravenous RZB induction dose, significantly greater rates of symptom improvement vs PBO were achieved. Improvements could be observed as early as Week 1 and were predictive of Weeks 12 and 52 clinical and endoscopic improvement.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Crohn DiseaseAntibodies, MonoclonalHumansMaleFemaleAdultSeverity of Illness IndexTreatment OutcomeRemission InductionMiddle AgedPatient Reported Outcome MeasuresDouble-Blind Method

Stichwörter der Autor:innen

Crohn’s diseaseRisankizumabearly symptom improvementpatient-reported outcomes

Substanzen

risankizumabAntibodies, Monoclonal

Autor:innen und Institutionen

  • The Henry D. Janowitz Division of Gastroenterology, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Department of Medicine I, University Hospital Schleswig-Holstein, Christian-Albrechts-University, Kiel, Germany.
  • Department of Gastroenterology, Amsterdam University Medical Center, Amsterdam, The Netherlands.
  • AbbVie Inc, North Chicago, Illinois, USA.
  • AbbVie Deutschland GmbH & Co KG, Ludwigshafen, Germany.
  • Department of Gastroenterology, Hepatology & Nutrition, Inflammation and Immunity, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Remo Panaccione

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Colombel, J. F., Schreiber, S., D'Haens, G., Rizzo, J., Kligys, K., Griffith, J., Zambrano, J., Zhou, Q., Zhang, Y., Kalabic, J., Rieder, F., Dubinsky, M. C., & Panaccione, R. (2024). Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies. Journal of Crohn's and Colitis, 18(6), 818-827. https://doi.org/10.1093/ecco-jcc/jjad206

Vancouver

Colombel JF, Schreiber S, D'Haens G, Rizzo J, Kligys K, Griffith J, et al. Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies. Journal of Crohn's and Colitis. 2024;18(6):818-827. doi:10.1093/ecco-jcc/jjad206

BibTeX
@article{Colombel2024,
  author = {Colombel, Jean-Frederic and Schreiber, Stefan and D'Haens, Geert and Rizzo, Joanne and Kligys, Kristina and Griffith, Jenny and Zambrano, Javier and Zhou, Qian and Zhang, Yafei and Kalabic, Jasmina and Rieder, Florian and Dubinsky, Marla C and Panaccione, Remo},
  title = {Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn’s Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies},
  journal = {Journal of Crohn's and Colitis},
  year = {2024},
  volume = {18},
  number = {6},
  pages = {818--827},
  doi = {10.1093/ecco-jcc/jjad206}
}
Kostenlos starten →